Caris Life Sciences recently announced that it has enhanced its comprehensive tumor profiling service, Caris Molecular Intelligence, which is now capable of providing 51 drug target associations, including new immunologically-based drug targets. Through these enhancements, Caris Molecular Intelligence will provide oncologists with more potentially useful treatment information for some of the most challenging cancers, including ovarian, head and neck, sarcoma, melanoma, and non-small cell lung cancers (NSCLC).
Caris Molecular Intelligence now offers a number of protein targets, including PD-1, a protein expressed by the immune cells (e.g., T cells) that can help cancerous cells evade the immune system. A number of pharmaceutical companies have promising lead drugs targeting PD-1 in current clinical trials for melanoma, such as immunotherapies like nivolumab and lambrolizumab. These drugs block the PD-1 protein and help the immune system recognize and attack melanoma cells. PD-1 and its ligand PD-L1 both have shown great promise in clinical trials for NSCLC as well.
The addition of certain key markers will continue to enhance the service’s existing clinical utility by expanding the associations to platinum-based therapies such as cisplatin, carboplatin, and oxaliplatin. These therapies are commonly prescribed in ovarian cancer, sarcomas, and other tumor types.
Caris Molecular Intelligence’s Clinical Trials Connector has also been substantially upgraded, including a real-time feed from www.clinicaltrials.gov that is updated nightly. The Clinical Trials Connector will also now only display results from open and enrolling trials to improve accuracy and efficiency, as well as include more nuanced filtering abilities, such as side-by-side trial comparison. Read more about Caris Molecular Intelligence Services.